TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement on cognitive measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean daily dose of ultraviolet radiation (UVR) to the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to device failure
Endpoint domain: Mortality/survival
Primary endpoint: Number, nature and severity of challenges or complications during surgical procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Number, nature and severity of device-related adverse events and incidents until device failure or explantation
Endpoint domain: Adverse events/effects
Primary endpoint: SOGS (South Oaks Gambling Screen)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dannon Ainhold Gambling Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical success of Pancreatic Retrograde Venous Infusion (PRVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Grade 3, 4, and 5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Vasopressor dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changed perception of Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of active breakdown products of NGM and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients cured
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients completed treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients died
Endpoint domain: Mortality/survival
Primary endpoint: Perceived severity of breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Affective distress of breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dyspnea with activities of daily living and exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cmax for single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast for single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-6 for single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Activities of Daily Living scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Scores on the Young Mania Rating Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state pharmacokinetics of buprenorphine and norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPPM pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Cell Count Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pictorial blood loss assessment chart (PBAC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate number of targeted problems
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reach of web-based intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Utilization of web-based intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction, use and barriers ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost to maintain the site content
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acute renal failure during post-operative ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative cerebrovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastric Emptying Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Small Bowel Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Screen positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screen false-positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uninformative test rate in cfDNA screening for 22q11.2 deletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and intensity of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline facial swelling (edema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of the Auditory Hallucination Rating Scale (AHRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement via Investigator Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: transplant free survival
Endpoint domain: Mortality/survival
Primary endpoint: Diaphragm dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of fear of childbirth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anesthesia Nontechnical skills score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 and 10-year local recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Identification of gut microbiome biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of OPB-51602
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Depression Pre-Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of Depression Post-Treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of Depression 1-year Follow-up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of Symptoms of Insomnia Pre-treatment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Absence of Active ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Unfavorable Structural Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Internerve variability of cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ulnar nerve CSA variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median nerve CSA variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Percent Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent Substance Use Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Rate at 12 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with atrial fibrillation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Steady-state plasma concentrations of efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison of anti-PT GMTs (IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates of subjects with anti-PT antibody titers at 3 years after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates of subjects with ≥ 4-fold increase in anti-PT antibody titers at 3 years after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in clinical evaluation at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in fibrous cap thickness at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final effective therapeutic decision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of late medical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sport injuries during physical activity lessons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clean urine THC samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety use of TDF
Endpoint domain: Adverse events/effects
Primary endpoint: 25 hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stool output rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Metres covered during 6 Minute Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease the swelling of the upper limb gradually
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency of the dialysis access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficient dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classifications of Henle's trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment, Assignment to Treatment, and Retention Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Days on Which Participants Experienced Each Reason for Attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Study Days With Protocol Non-Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication Acceptability for Completers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complications arising from embolization
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of cancerous cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peak plasma concentration (Cmax) of Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration (Tmax) of Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (T1/2) of Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Adherence to Lumacaftor/Ivacaftor Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention in care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum tolerated dose (MTD) of nintedanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inactivation of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of New Gadolinium (Gd) Enhancing T1-hyperintense Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Contraction frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip related complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: serum ALT (unit/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: serum AST (unit/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of ABBV-221
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleed Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Burden
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Revision Surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and reactogenicity of the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Treated Subjects Diagnosed With Longstanding Persistent AF Off Class I or III Antiarrhythmic Drugs and Out of AF at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Device and Procedure Related Acute Major Adverse Events (MAE) Within 30 Days Post-procedure or Prior to Hospital Discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Oocyte recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in HIV status based on viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in HIV status based on CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parental overall acceptance of SDF staining
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin self-examination rates
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: QT and QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Understanding of CNS metastases biology using CSF-ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in minimum masking levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tinnitus percept as assessed via the visual analog test of tinnitus loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and proportion of subjects with biopsy-proven rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HTN control into guideline specified range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complutense Verbal Learning Test (TAVEC) - Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digits Wechsler Intelligence Scale for Adults-III (WAIS-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hemoglobin A1C change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with average system leak >60L/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% Reduction in Physician's Global Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal change in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: screw placement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: radiation exposure
Endpoint domain: Physiological/clinical
Primary endpoint: Rate of Facial Hair Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy related sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composition of T cells, B cells, NK cells and monocyte populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma levels in activated T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antigen specific B cells measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total amount of phenylephrine needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hooper's index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: handgrip strength (in Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lactate (µmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful Epidural Blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and tolerability of Menadione Topical Lotion
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic absorption of Menadione Topical Lotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat mass and lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial health via flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood glucose testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailable Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in scores on the Coping Strategies Questionnaire-French version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving LDL-cholesterol goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of medications in urine and blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Identifying With Themes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change scores on the Suicide Behaviors Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in knee OA
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical symptoms in knee OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and emotional factors in knee OA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: microvascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of symptomatic TE events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Use of tumor markers in cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of Action
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in KOOS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline gene mutation status at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from second line gene mutation status at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treatment failure within 72 hours after randomization
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Public Speaking Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Persistence of saphenous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in dietary variety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of stride length (meter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of cadence (step/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of duration of stance phase (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal bacterial population(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delta-work efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensitivity and specificity of the FISH technique for the detection of the ALK rearrangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum vertical jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Local Solicited Adverse Event (AE) Post Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Systemic Solicited AE and Related Systemic Solicited AE Post Dose 1
Endpoint domain: Adverse events/effects